Patent ID: 11890327
Assignee: CSL BEHRING LENGNAU AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A method for the treatment of a blood coagulation disorder, comprising administering an effective amount of (i) a recombinant polypeptide consisting of (a) a truncated von Willebrand Factor (VWF) and (b) at least one non-VWF sequence, and (ii) a Factor VIII protein (FVIII) to a subject having a blood coagulation disorder,
wherein at least one of the non-VWF sequences is a half-life extending moiety (HLEM),
wherein the truncated VWF has a sequence identity of at least 90% to amino acids 764 to 1242 of SEQ ID NO:4,
wherein at least one of the recombinant polypeptide and the FVIII is administered extravascularly,
wherein the recombinant polypeptide is present as a dimer and wherein the ratio of dimer:monomer of the recombinant polypeptide is at least 1.5,
wherein said dimeric recombinant polypeptide is capable of binding to said FVIII and has a FVIII binding affinity characterized by a dissociation constant KD of less than 1 nM, and
wherein the molar ratio of the recombinant polypeptide to the FVIII is higher than 50.